WELCOME to epgonline.org

Welcome to epgonline.org, a free online source of credible and independent scientific content intended for healthcare professionals in the United Kingdom that brings all the medical information you need into one place, providing education and guidance to help with the diagnosis and treatment of your patients.

This website provides:

  • Drug information, categorised using the ATC Classification System, providing indication, dosage, administration and precautions.
  • Specialty and disease information, categorising specialties and diseases using the ICD-10 classification, with further insight found in the Disease Focus area.
  • The Horizons series of articles, written by our team of specialists, that ask what the future of healthcare holds, evaluating emerging trends to provide expert insight.
  • The latest news to keep you up-to-date with current advancements in drug development, advocacy and awareness, industry mergers and acquisitions, clinical trial progression and congress information.
  • Recent opinion articles shared with us by healthcare professionals to express their views and experiences.
  • A wide variety of accredited internal and external CME modules and courses, designed to educate on the latest care strategies for specific conditions.
  • The latest studies, trials and guidelines from global publications provide a comprehensive collection of current and past developments in medicine, helping you to provide best practice.
  • Medical applications that deliver creative solutions to aid in the diagnosis and treatment of your patients.
  • Specialist educational microsites, or Learning Zones, each devoted to self-directed medical education surrounding a specific disease, condition or procedure.

Registration is quick and simple, giving you unlimited access to all content and features, allowing you to save pages, comment on your favourite articles and access the personalised dashboard.

Latest News

Added 2 hours ago Drug news

FDA approves Tibsovo to treat AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.- Agios Pharma.

Agios Pharmaceuticals, Inc. has announced that Tibsovo (ivosidenib) was granted approval from the FDA for the treatment of adult patients...

Added 2 hours ago Drug news

FDA approval of Tibsovo to treat AML is based on Study AG120-C-001, NCT02074839.- Agios Pharma.

The FDA approval for Tibsovo (ivosidenib) was based on the clinical data from an open-label, single-arm, multicenter dose-escalation and expansion...

Added 2 hours ago Drug news

Successful Phase III study of Vyxeos compared to standard of care for AML is published in the Journal of Clinical Oncology.

Jazz Pharmaceuticals plc announced that data from the pivotal Phase III study of Vyxeos (daunorubicin and cytarabine) liposome for injection...

Looking to the horizon - Breakthrough drugs and treatments

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 1 year ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 7 months ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Selected congress insight

Alex Keen

ECCMID 2018 ‒ Antibiotic resistance: an immediate and growing threat

Posted 3 months ago

This year’s ECCMID is hosting a large number of sessions discussing antibiotic resistance, an immediate and pressing issue that has been described as ‘one of the biggest threats to global health, food security, and development today'.

Allen Wellings

ELCC 2018 ‒ Roundup of this year’s conference

Posted 3 months ago

At the recent ELCC, held from 11‒14 April 2018, several hundred abstracts were presented detailing the latest cutting-edge research in lung cancer treatment and care. Brief summaries of some of the key abstracts are found here.

Alex Keen

ILC 2018 – Targetable pathways in liver disease: from identification to clinical application

Posted 3 months ago

A number of studies from the speakers at this year's ILC Basic Science Seminar are discussed here, focusing on targetable pathways in liver disease, covering pathway identification, potential drug targets and their clinical application.

Alex Keen

EBCC 2018 – The multidisciplinary approach to breast cancer care

Posted 4 months ago

The focus of this year’s European Breast Cancer Conference is the importance of multidisciplinary working. Explore the origins of multidisciplinary cancer care and the evidence surrounding it.